AR and neoplasm: Additional molecular findings were low to medium HER2-expression in 3 patients, PD-L1 expression in 2 patients, a tumor mutational burden (TMB) > 10 mutations/Megabase (mut/Mb) and an AR mutation in 1 patient, each.